Essay On Acute Myeloid Leukemia - 1028 Words

In 2014, cancer is the second primary cause of death in the United States(US) and it kills approximately 311,296 and 280,403 men and women respectively. The rate of mortality from 2009 to 2013, of leukemia in men and women is 14.5. Moreover, the mortality rate in both male and female suffering from Acute myeloid leukemia (AML) is 5.9 comparing to 0.9 in Acute lymphocytic leukemia(ALL).1 Attacking the bone marrow, blood, and other tissues by irregular recognize are properties of AML that distinguish it from other classes of cancers. In addition, fifty years ago, AML was a fatal disease. Nowadays, there are improvement of AML in 35 to 40% of adult patients who are ≠¤ 60 years old, but in patients 60 years old, represent about 5 to†¦show more content†¦The CD33-targeting antibody-drug conjugates hold a poison load and it was established to improve the therapy outcome. Therefore, calicheamicin was the type of poison that chosen and then it can target the leukemia cells.5 Hepatic sinusoidal obstruction syndrome (SOS) is a serious side effect that appear after using GO drug also known as veno-occlusive disease (VOD). Losing weight, yellow eyes color and ascites are sign/symptom of SOS. 6 Serious side effects can harm the patients and leads to mortality. Accelerated approval of GO in 2000 by FDA was depend on results of 3 phase II clinical trial studies that contains 142 patients with AML diseases. Later, the rest of the patients was finished almost 277. Sinusoidal obstructive syndrome (SOS) or hepatic veno-occlusive disease (VOD) is a serious side effect was appearing in these 3 studies of using GO monotherapy in 2 of 142 patient.7 Safety reports were analyzed to explore the association between SOS with GO from observational studies and clinical trials. Also, temporary record from FDA mandated Prospective Observational Registry and Food Drug Administration’s Adverse Event Reporting System(FAERS). Occurrence frequency by Medline searches was describing the comparative rates of SOS without GO and the connection of GO with SOS. If the stem cell transplantation (SCT) was completed for 90 days of GO management, the range in observational studies of SOS was from 15 to 40%.